Filing summary
Entity mismatch: The request identifies Nexttrip, Inc., but the supplied 10-K is for Sigma Labs, Inc. (NASDAQ: SGLB). This summary covers the filing actually provided.
Business context and reporting period
Annual report for the fiscal year ended December 31, 2021, compared with fiscal 2020; it is not a quarterly filing. Sigma develops PrintRite3D, an in-process quality-assurance platform for additive manufacturing, and earns revenue from software and related hardware sales, maintenance, engineering services, and contract manufacturing.
Key financial metrics
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | $1.652 million | $0.807 million |
| Gross profit / margin | $1.092 million / 66% | $0.216 million / 27% |
| Operating expenses | $9.571 million | $5.914 million |
| Loss from operations | $8.479 million | $5.699 million |
| Net loss | $7.385 million | $5.200 million |
| Net loss applicable to common stockholders | $7.488 million; $0.76 per share | $7.009 million; $1.83 per share |
| Cash used in operating activities | $6.299 million | $4.810 million |
| Cash and working capital at year-end | $11.447 million / $11.702 million | $3.701 million / $4.332 million |
Cash used in investing activities was $0.360 million; cash provided by financing activities was $14.405 million. Year-end total liabilities were $0.981 million, consisting of current liabilities; the balance sheet reports no long-term liabilities. The filing reports no income tax provision. Sigma had no material funded debt shown on the balance sheet, but continued to consume cash and relied on securities offerings and warrant exercises for funding.
Changes versus the prior year
- Revenue more than doubled, up $0.844 million, primarily from increased PrintRite3D system sales; the company sold 11 units versus 6 in 2020.
- Gross margin rose 39 percentage points, which management attributed to lower component costs, product redesign, more efficient installations, shorter RTE evaluations, and lean manufacturing.
- Operating expenses rose $3.657 million, driven in part by hiring, compensation, stock-based awards, R&D, professional services, and travel. Operating loss widened by $2.781 million.
- Net loss applicable to common stockholders increased by $0.479 million, despite lower preferred dividends. 2021 other income included a $1.092 million noncash gain from remeasurement of warrants before their reclassification to equity.
- Cash increased after 2021 equity financing: public offerings generated approximately $13.269 million net, with another $1.136 million from warrant exercises. Common shares outstanding rose from 5.995 million to 10.499 million.
Outlook, commentary, risks, and unusual items
- Management said existing cash was expected to fund operations and capital needs through 2022, while also stating that additional financing would be needed to fund operations, maintain Nasdaq compliance, and execute its plan. The company cautioned that estimates depend on assumptions and future funding is not assured.
- The announced three-year strategy included subscription pricing intended to lower upfront customer cost from more than $100,000 to about $3,000–$4,000 per month, expanded OEM distribution, and a transition toward software-only offerings intended to improve affordability and gross margins. These are plans, not reported results.
- Management reported that two international OEM partners generated less 2021 revenue than projected, citing sales-force ramp time, COVID-related impacts, and limited sales into certain regulated verticals. COVID-related customer capital-spending delays and uncertainty remain risks.
- Revenue concentration was substantial: two customers accounted for 27.81% and 17.23% of 2021 revenue. Two customers represented 51.25% and 46.34% of year-end receivables, respectively.
- Potential dilution is significant: at year-end, the company disclosed 3.988 million warrants, 1.396 million options, and preferred securities convertible into common shares; total potential additional shares were approximately 5.533 million. Preferred Series D terms include potential redemption at a 125% premium upon specified triggering events, including Nasdaq listing failure.
- Other key risks include recurring losses, future financing and Nasdaq listing requirements, competition, customer adoption, supplier delays and costs, intellectual-property protection, and dependence on key personnel. No legal proceedings were reported.
- After year-end, Jacob Brunsberg became President and COO; Mark Ruport remained CEO and director but resigned as President. Sigma also reported a Materialise technology collaboration and an Aconity3D integration initiative.
- The auditor gave an unqualified opinion on the financial statements. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor did not attest to ICFR. The audit identified revenue recognition for contracts with multiple deliverables as a critical audit matter.
Important facts for investors to verify
- Confirm the intended issuer: the provided filing is Sigma Labs, Inc., not Nexttrip, Inc.
- Review the audited statements and notes for the treatment of warrant-related income, preferred dividends, and potential dilution.
- Reconcile the filing’s liquidity and financing statements with its assertion that cash funds operations through 2022 while additional financing is required.
- Check the CARES Act payroll-tax disclosures: the balance sheet reports no such liability at year-end, while a note describes $37,728 due in 2022.
- Track actual subscription adoption, OEM sales, software-only transition, customer concentration, and subsequent cash burn against management’s plans.